Sequential Inhibitor Therapy in CML: In Vitro Simulation Elucidates the Pattern of Resistance Mutations after Second- and Third-Line TreatmentBAUER, Robert C; SÄNGER, Jana; PESCHEL, Christian et al.Clinical cancer research (Print). 2013, Vol 19, Num 11, pp 2962-2972, issn 1078-0432, 11 p.Article

Changes in mutational status during third-line treatment for metastatic colorectal cancer—Results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasmaSPINDLER, Karen-Lise Garm; PALLISGAARD, Niels; ANDERSEN, Rikke Fredslund et al.International journal of cancer (Print). 2014, Vol 135, Num 9, pp 2215-2222, issn 0020-7136, 8 p.Article

The Evaluation of E-Cadherin and Vimentin as Biomarkers of Clinical Outcomes Among Patients with Non-small Cell Lung Cancer Treated with Erlotinib as Second- or Third-line TherapyRICHARDSON, Frank; DAVID YOUNG, G; SENNELLO, Regina et al.Anticancer research. 2012, Vol 32, Num 2, pp 537-552, issn 0250-7005, 16 p.Article

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDCKO, J. J; CHOUEIRI, T. K; WOOD, L et al.British journal of cancer. 2014, Vol 110, Num 8, pp 1917-1922, issn 0007-0920, 6 p.Article

Evaluation of Amrubicin as a Third or Later Line of Chemotherapy for Advanced Non-Small Cell Lung CancerIGAWA, Satoshi; SASAKI, Jiichiro; ISHIHARA, Mikiko et al.Chemotherapy (Basel). 2013, Vol 59, Num 2, pp 99-105, issn 0009-3157, 7 p.Article

An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancerHORGAN, A. M; BRADBURY, P. A; AMIR, E et al.Annals of oncology. 2011, Vol 22, Num 8, pp 1805-1811, issn 0923-7534, 7 p.Article

Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysisMONTEMURRO, M; GELDERBLOM, H; PINK, D et al.European journal of cancer (1990). 2013, Vol 49, Num 5, pp 1027-1031, issn 0959-8049, 5 p.Article

The Need for Third-line Treatment in Non-small Cell Lung Cancer: An Overview of New OptionsSYRIGOS, Kostas N; SAIF, Muhammad W; KARAPANAGIOTOU, Eleni M et al.Anticancer research. 2011, Vol 31, Num 2, pp 649-659, issn 0250-7005, 11 p.Article

Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trialROSSI, David; DENNETTA, Donatella; UGOLINI, Marcello et al.Targeted oncology. 2010, Vol 5, Num 4, pp 231-235, issn 1776-2596, 5 p.Article

Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapyIBRAHIM, Amr R; PALIOMPEIS, Christos; DAZZI, Francesco et al.Blood. 2010, Vol 116, Num 25, pp 5497-5500, issn 0006-4971, 4 p.Article

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)KAWAGUCHI, Tomoya; ANDO, Masahiko; KAMIMURA, Mitsuhiro et al.Journal of clinical oncology. 2014, Vol 32, Num 18, pp 1902-1908, issn 0732-183X, 7 p.Article

Impacts of Treatment Lines and Initiation Timing of Erlotinib for Advanced Non-small Cell Lung CancerAOKI, Takuya; IGAWA, Satoshi; MASUDA, Noriyuki et al.Anticancer research. 2012, Vol 32, Num 2, pp 601-608, issn 0250-7005, 8 p.Article

Second and third line treatment in non-small cell lung cancerFAVARETTO, Adolfo; PASELLO, Giulia; MAGRO, Cristina et al.Critical reviews in oncology/hematology. 2009, Vol 71, Num 2, pp 117-126, issn 1040-8428, 10 p.Article

Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II studyTIEN HOANG; CAMPBELL, Toby C; JOHNSON, Peter H et al.Investigational new drugs. 2014, Vol 32, Num 1, pp 195-199, issn 0167-6997, 5 p.Article

Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancerSHAO, Yu-Yun; SHAU, Wen-Yi; LIN, Zhong-Zhe et al.European journal of cancer (1990). 2013, Vol 49, Num 1, pp 106-114, issn 0959-8049, 9 p.Article

Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC)LANGER, Corey J; MOK, Tony; POSTMUS, Pieter E et al.Cancer treatment reviews. 2013, Vol 39, Num 3, pp 252-260, issn 0305-7372, 9 p.Article

Phase 2 Study of Nilotinib as Third-Line Therapy for Patients With Gastrointestinal Stromal TumorSAWAKI, Akira; NISHIDA, Toshirou; DOI, Toshihiko et al.Cancer. 2011, Vol 117, Num 20, pp 4633-4641, issn 0008-543X, 9 p.Article

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitorsSOVERINI, Simona; GNANI, Alessandra; LACOBUCCI, Ilaria et al.Blood. 2009, Vol 114, Num 10, pp 2168-2171, issn 0006-4971, 4 p.Article

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancerKANG, Yoon-Koo; MURO, Kei; RYU, Min-Hee et al.Investigational new drugs. 2014, Vol 32, Num 2, pp 355-361, issn 0167-6997, 7 p.Article

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECORAY-COQUARD, I; FAVIER, L; PUJADE-LAURAINE, E et al.British journal of cancer. 2013, Vol 108, Num 9, pp 1771-1777, issn 0007-0920, 7 p.Article

Au-delà de la première ligne: les lignes ultérieures de traitement : Cancers du poumon = Beyond first-line: post-treatment optionsDANSIN, E; FERTE, C.La Lettre du cancérologue (Boulogne). 2011, Vol 20, Num 6, pp 394-398, issn 1165-113X, 5 p.Article

Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010FELIP, E; GRIDELLI, C; BAAS, P et al.Annals of oncology. 2011, Vol 22, Num 7, pp 1507-1519, issn 0923-7534, 13 p.Article

Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal CancerBENDELL, Johanna C; NEMUNAITIS, John; VUKELJA, Sasha J et al.Journal of clinical oncology. 2011, Vol 29, Num 33, pp 4394-4400, issn 0732-183X, 7 p.Article

Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: A phase II studyROSATI, Gerardo; ROSSI, Antonio; GERMANO, Domenico et al.Anticancer research. 2003, Vol 23, Num 3C, pp 2981-2985, issn 0250-7005, 5 p.Article

Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: A mono-institutional experiencePASELLO, Giulia; NICOTRA, Samuele; MARULLI, Giuseppe et al.Lung cancer. 2011, Vol 73, Num 3, pp 351-355, issn 0169-5002, 5 p.Article